US FDA adds Mahendra Chemicals to import alert "Red List"

By Gareth Macdonald

- Last updated on GMT


Related tags Pharmaceutical drug Food and drug administration Fda

Mahendra Chemicals has been banned from shipping drug ingredients made at its plant in Ahmedabad, India to the US.

The active pharmaceutical ingredient (API) manufacturer - whose products include antibiotics and lidocaine - was added to the US Food and Drug Administration’s (FDA) 66-40 import​ alert list – also known as the “Red List” – last Friday.

According to the FDA, companies are subject to an import alert when an “inspection has revealed that a firm is not operating in conformity with current good manufacturing practices (GMP's)​.”

No further details were provided. Mahendra’s inclusion on the import alert means its products can be detained at US borders.

The firm did not respond to a request for comment.

Mahendra's last run-in with the US FDA was in July 2015​ when it received a warning letter detailing problems observed at the Ahmedabad site during an inspection in May 2014.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more